Growth Clinical Trials

144 recruitingLast updated: July 25, 2026

There are 144 actively recruiting growth clinical trials across 48 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Growth Trials at a Glance

144 actively recruiting trials for growth are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Not Applicable with 31 trials, with the heaviest enrollment activity in Boston, Houston, and Dallas. Lead sponsors running growth studies include Aga Khan University, Ascendis Pharma Endocrinology Division A/S, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Growth Clinical Trials

Looking for clinical trials for Growth? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Growth trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Growth clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 144 trials

Recruiting

Study of Proteus Syndrome and Related Congenital Disorders

Proteus SyndromePIK3CA Related Overgrowth Spectrum
National Human Genome Research Institute (NHGRI)1,500 enrolled1 locationNCT00001403
Recruiting

Placental Biology in Health and Disease

PregnancyPre-EclampsiaFetal Growth Restriction (FGR)+3 more
University of Oxford360 enrolled1 locationNCT07470320
Recruiting

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Turner SyndromeGrowth Hormone DeficiencySmall for Gestational Age+1 more
Dong-A ST Co., Ltd.5,000 enrolled1 locationNCT04798690
Recruiting
Phase 3

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Growth Hormone Deficiency (GHD)
Lumos Pharma150 enrolled42 locationsNCT06948214
Recruiting
Not Applicable

Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants

Infant DevelopmentInfant Nutritional Physiological PhenomenaInfant Formula+2 more
Société des Produits Nestlé (SPN)234 enrolled5 locationsNCT05868408
Recruiting

Placental Progesterone Membrane Receptors in Fetal Growth Restriction

PregnancyFetal Growth RestrictionPlacenta+4 more
Samsun University90 enrolled1 locationNCT07701837
Recruiting
Phase 1Phase 2

Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

Spasticity, MuscleSpastic ParaplegiaMicrocephaly+3 more
Elpida Therapeutics SPC4 enrolled1 locationNCT05518188
Recruiting
Phase 3

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

Mild Traumatic Brain InjuryAdult Growth Hormone Deficiency
VA Office of Research and Development172 enrolled16 locationsNCT04867317
Recruiting
Phase 2

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled35 locationsNCT06997588
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting

The Growing Well Study

Dental health.Dietary BehaviorsDietary Intakes+1 more
University of Leeds1,890 enrolled6 locationsNCT07698158
Recruiting
Phase 2

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd.35 enrolled2 locationsNCT07518160
Recruiting
Not Applicable

Efficacy of Vicarious Post-Traumatic Growth Intervention for Nurses in Emergency Units

Psychological DistressPsychological Well-beingVicarious Trauma+1 more
Fatima Jinnah Women University60 enrolled1 locationNCT07677527
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Not Applicable

Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program

Skin CancerSkin Cancer PreventionBenign Skin Growth
National University Hospital, Singapore280 enrolled1 locationNCT07247123
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd.141 enrolled15 locationsNCT06975618
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting

Evaluation of Children With Endocrine and Metabolic-Related Conditions

Metabolic DiseaseAdrenal InsufficiencyBone Diseases, Metabolic+2 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)15,000 enrolled1 locationNCT02769975
Recruiting

Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.

Isolated Non-acquired Growth Hormone Deficiency
Assistance Publique - Hôpitaux de Paris200 enrolled1 locationNCT07333521
Recruiting

Genotype/Phenotype Correlation of MORC2 Mutations

Impaired growthCharcot-Marie-Tooth diseaseDevelopmental Delay Disorder+2 more
Hospices Civils de Lyon45 enrolled12 locationsNCT07038239